[Biotech&Pharma] FDA Grants Priority Review Designation For Clovis Oncology's Rubraca Label Expansion

Browse By

Clovis Oncology Inc (NASDAQ: CLVS) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug Rubraca.

The Boulder, Colorado-based biopharma company that focuses on the development of anti-cancer agents said the FDA has accepted its sNDA for rucaparib as a monotherapy for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.

Clovis had submitted the regulatory application in November.

See Also: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, …

Full story available on Benzinga.com

Source Benzinga

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.